Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
The primary specific aim is to examine the efficacy of Paliperidone extended release Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) compared to placebo in decreasing manic symptoms in patients with comorbid DSM-IV bipolar disorder and alcohol dependence. The investigators hypothesize that the Paliperidone Palmitate Injection (INVEGA® SUSTENNA™) treated group will have a statistically significant advantage on improvement in manic symptoms. They will also have higher rate of treatment response and remission.
Epistemonikos ID: 83799190502d4ed9bafb29cfd384bc640c397474
First added on: May 05, 2024